Gridley D S, Smith T E, Liwnicz B H, McMillan P J
Department of Microbiology, Loma Linda University/Independent Order of Foresters Cancer Research Laboratory, Loma Linda University School of Medicine, CA 92350.
Anticancer Res. 1994 Nov-Dec;14(6B):2493-500.
The purpose of this study was to determine if proton irradiation can increase the localization of radiolabeled monoclonal antibodies (MAb) in subcutaneous (s.c.) or intracranial (i.c.) human lung tumors xenotransplanted in athymic rats. Rats with carcinoembryonic antigen (CEA)-expressing (NCI-H441) tumors were irradiated using 3 different proton time-dose regimens, followed by 111In-ZCE025, an anti-CEA MAb, which was injected 2 hr after the last dose of irradiation, and the animals were euthanized 3 days later for biodistribution and other assays. Proton irradiation at 10 gray (Gy) as a single dose or in 2 Gy fractions given on 5 consecutive days increased the uptake of 111In-ZCE025 into s.c. tumors by 292% and 182%, respectively, compared to nonirradiated controls. No enhancement in radiolabeled MAb delivery was seen after hemibrain irradiation in animals with i.c. tumors. Histopathological examination of both implantation sites showed a viable poorly differentiated adenocarcinoma with a decrease in blood vessel density, a decrease in mitotic activity, and an increase in areas of necrosis following irradiation as compared with adjacent nonirradiated tissue. CEA expression was generally maintained in vivo in that the marker was detectable in the tumor, plasma, and cerebrospinal fluid. Oxygen radical production by peripheral blood cells from s.c. and i.c. tumor-bearing rats exhibited strikingly different patterns of responsiveness. I.c. injected animals were 24% lighter than their s.c. injected counterparts, but no neurological signs of tumor progression were noted. The results indicate that proton irradiation can be used effectively to increase the delivery of radiolabeled MAb to s.c. implanted human lung tumor xenografts. However, in order to accomplish this in the brain, other radiation time-dose schedules and treatments may be needed.
本研究的目的是确定质子辐照是否能增加放射性标记单克隆抗体(MAb)在无胸腺大鼠体内皮下(s.c.)或颅内(i.c.)移植的人肺肿瘤中的定位。将表达癌胚抗原(CEA)的(NCI-H441)肿瘤大鼠使用3种不同的质子时间-剂量方案进行辐照,随后注射抗CEA单克隆抗体111In-ZCE025,在最后一剂辐照后2小时注射,3天后对动物实施安乐死以进行生物分布和其他检测。与未辐照的对照组相比,单次剂量10格雷(Gy)的质子辐照或连续5天每天给予2 Gy分次剂量的质子辐照分别使111In-ZCE025在皮下肿瘤中的摄取增加了292%和182%。在患有颅内肿瘤的动物中,半脑辐照后未观察到放射性标记单克隆抗体递送增强。对两个植入部位的组织病理学检查显示,与相邻未辐照组织相比,存在存活的低分化腺癌,血管密度降低,有丝分裂活性降低,辐照后坏死区域增加。CEA表达在体内通常得以维持,因为该标志物在肿瘤、血浆和脑脊液中均可检测到。来自皮下和颅内荷瘤大鼠的外周血细胞产生氧自由基表现出截然不同的反应模式。颅内注射的动物比皮下注射的动物轻24%,但未观察到肿瘤进展的神经学体征。结果表明,质子辐照可有效用于增加放射性标记单克隆抗体向皮下植入的人肺肿瘤异种移植物的递送。然而,为了在脑内实现这一点,可能需要其他辐射时间-剂量方案和治疗方法。